Black triangle scheme
Black triangle medicinal products are subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
Black triangle medicinal products currently in MIMS include apalutamide (Erlyand), avelumab (Bavencio), baricitinib (Olumiant), cabozantinib (Cabometyx), dupilumab (Dupixent), everolimus (Afinitor), glecaprevir/pibrentasvir (Maviret), ixekizumab (Taltz), lurasidone hydrochloride (Latuda), rufinamide (Inovelon) and sofosbuvir/velpatasvir/voxilaprevir (Vosevi).
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629